Acrivon Therapeutics, Inc. Common Stock

NASDAQ:ACRV

Biotechnology

Healthcare
$1.56 +3.16%

+$0.05 today

Market cap
$66.94M
Beta
1.91
P/E (TTM)
-0.8
EPS (TTM)
-$2.00
52W Low $1.15High $3.56

Volume 0.61M

Average 0.60M

ACRV Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Acrivon Therapeutics, Inc. Common StockNASDAQ: ACRV

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses declines year over year

Q1 FY2026 other income / expenses of $860K fell 56.6% year over year, behind the -46.1% change in trailing-twelve-month other income / expenses. Sequentially, it fell 24.0% from the prior quarter. Over 3 fiscal years it compounded at +60.9% a year.

Context

  • Other income / expenses increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -56.6% toward the trailing-twelve-month pace of -46.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$860K-24.0% QoQ
Last fiscal yearDec 2025
$6.21M-28.2% YoY
LTMMar 2026
$5.09M-46.1% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-56.6%——
1 year-28.2%——
3-year CAGR+60.9%——
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
6.21M USD
Year-over-year change
-28.2%

Other Income / Expenses vs competitors

How ACRV compares with its peers on the latest reported figures

  • ACRV's LTM Mar 2026 other income / expenses of $5.09M is the 4th highest of the 10 companies compared; the peer median is $3.26M.
  • Its year-over-year change of -46.1% is the 7th highest of 10, against a peer median of -10.4%.
  • Over three fiscal years its annual growth of +60.9% compares with a peer median of +49.0%.
ACRV Competitors Peer median
Other Income / Expenses for ACRV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMEABiomea Fusion, Inc.LTM Mar 2026$21.62M +427.9%+121.1%—
IMUXImmunic, Inc.LTM Mar 2026$5.35M +16.3%——
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$5.34M -44.5%+19.2%—
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$5.09M -46.1%+60.9%—
TCRXTScan Therapeutics, Inc.LTM Mar 2026$4.4M -46.5%+144.2%48.1%
ATYRaTyr Pharma, Inc.LTM Mar 2026$3.26M -10.4%+49.0%1714.2%
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$1.47M -57.0%-25.8%—
VXRTVaxart, Inc.LTM Mar 2026-$675K -3.2%—0.3%
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026-$9.98M -163.6%——
CBUSCibus, Inc.LTM Mar 2026-$45.03M -1.1%—1050.7%
Peer median (excluding ACRV) $3.26M-10.4%+49.0%549.4%

Competitors are the stored peer set for ACRV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00536K1.01M1.36M
Gross Profit00(536K)(1.01M)(1.36M)
Gross Margin—————
Research & Development13.72M23.95M45.49M63.99M59.99M
Selling, General & Admin2.47M8.71M21.21M25.21M24.12M
Operating Expenses16.18M32.66M66.7M88.19M82.76M
Depreciation & Amortization37K364K536K1.01M1.36M
EBITDA(16.21M)(30.8M)(59.85M)(79.55M)(76.55M)
EBITDA Margin—————
Operating Income(16.18M)(32.66M)(67.24M)(89.2M)(84.11M)
Operating Margin—————
Interest Income007.04M9.2M6.48M
Interest Expense00000
Other Income / Expenses(59K)1.49M6.85M8.64M6.21M
Income Before Tax(16.24M)(31.17M)(60.39M)(80.56M)(77.91M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(16.24M)(31.17M)(60.39M)(80.56M)(77.91M)
Net Margin—————
EPS (Basic)(1.26)(1.42)(2.74)(2.10)(2.02)
EPS (Diluted)(1.26)(1.42)(2.74)(2.10)(2.02)
Weighted Avg Shares12.91M21.92M22.08M38.3M38.51M
Weighted Avg Shares (Diluted)12.91M21.92M22.08M38.3M38.51M

Acrivon Therapeutics, Inc. Common Stock

NASDAQ:ACRV

Intrinsic Alpha fair value

Locked

Current Price

$1.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.